A Travers Smith team led by corporate partner Helen Croke has advised Bridgepoint Development Capital on its acquisition of Quotient Clinical Limited and the associated equity arrangements.

Employing over 200 people, Quotient Clinical  specialises in early clinical development and has developed a platform which offers an integrated approach to formulation development, “real-time” drug product manufacturing and clinical testing. Using this platform has been proven to significantly reduce the time and cost of the early stage drug development process.

Quotient Clinical serves a global customer base comprising a range of top tier pharmaceutical companies through to small-medium sized biotech organisations. More than three quarters of its revenues are derived from customers based in the USA or mainland Europe. It has two operational facilities in the UK. The principal site in Nottingham, has a certified 85 bed clinical pharmacology unit with an integrated drug manufacturing facility employing formulation chemists, and clinical staff including nurses and doctors. The second facility in Edinburgh houses Quotient Clinical's Biometrics function responsible for the analysis and reporting of clinical trial data.

Corporate partner Helen Croke and associates Joanna Roberts, Ian Keefe and Tom Hartwright provided corporate law advice to Bridgepoint Development Capital. Tax advice was provided by a team led by tax partner Kathleen Russ and senior counsel Hannah Manning. The finance team was led by banking partner Matt Ayre and associates Kate Dickens and Jonathan Clapshaw.